The OpenArray(R) technology enables researchers to perform large-volume nanoliter arrays, conducting up to 3,000 assays simultaneously, while the RapidFire(R) Mass Spectrometry (RF-MS) technology uses microfluidics to conduct sample analysis 10-to-100 times faster than conventional liquid chromatography-mass spectrometry (LC-MS) technologies.
Collaborations with sector leaders such as Applied Biosystems, Agilent Technologies, BD Biosciences, Gene Express, MDS Analytical Technologies and Synchron Lab Automation have yielded optimized genotyping systems, end-to-end high-throughput mass spectrometry solutions, sample preparation and data analysis of high-throughput in vitro ADME assays, lead discovery and lead optimization services, and even a genetic profiling test for lung cancer risk. This successful business strategy enabled BioTrove to expand its own customer base and brand reputation, increasing distribution channels for RapidFire(R) and OpenArray(R) and expanding business.
“BioTrove has been proactive in partnering with scientists and clinicians to enable higher-throughput research leading to advances in healthcare,” added Bird. “The company is a blueprint for sound business strategy and demonstrates that quality and a collaborative spirit remain essential characteristics for successful life sciences companies.”
For exhibiting best practices in growth strategy, BioTrove is an ideal recipient of the Frost & Sullivan 2009 North American Drug Discovery Technologies Growth Strategy Leadership of the Year Award. Each year, Frost & Sullivan presents this award to the company that has demonstrated an exceptional growth strategy within the industry.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
BioTrove, Inc. offers two innovative technology platforms: OpenArray(R), which advances genomic research in a wide range of life science fields, including agriculture, disease research, and public health, and RapidFire(R), which enables the acceleration of drug discovery and pipeline decisions. With 11 of the 15 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BioTrove’s products and services ensure that an industry committed to accuracy and speed can meet business goals.
SOURCE Frost & Sullivan